ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD

Data ReadoutpositivetozorakimabPositive

AI Analysis

Summary

AstraZeneca presented full results from Phase III OBERON and TITANIA trials of tozorakimab, its IL-33 inhibitor for COPD, demonstrating groundbreaking exacerbation reduction at ERS 2026.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III OBERON and TITANIA trials showed groundbreaking exacerbation reduction

Importance:7/10

Sentiment:

0.75

IL-33 inhibitorCOPDexacerbation reductionPhase IIIOBERON trialTITANIA trialERS 2026

Related Companies

$AZN

Read the original article

Published by Clinical Trials Arena on September 9, 2026 2:56 PM

Read Original